Stockscreener 앱 받기
1.06
3.92%
0.04
Lisata Therapeutics Inc 주식(LSTA)의 최신 뉴스
Form PRE 14A Lisata Therapeutics For: 7 October By Investing.com - Investing.com India
A rare hormone disorder trial doses its first patient; its drug may allow shots every two weeks, not daily. - Stock Titan
Halper Sadeh LLC is Investigating Whether BWIN, LSTA, ACVA are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Lisata director holds preferred tied to 2.27M shares - Stock Titan
Lisata COO Holds Preferred Stock Tied to 2.54M Shares - Stock Titan
Lisata Therapeutics (LSTA) Buys Marea and Signs $225M Financing. Is the Dilution Worth it? - Yahoo Finance
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz - Pharmaceutical Executive
Lisata Therapeutics Acquires Marea, Refocuses on Cardioendocrine Portfolio - The Globe and Mail
Why Is Lisata Therapeutics (NASDAQ:LSTA) Becoming A Penny Stocks Test? - Kalkine Media
Lisata Therapeutics acquires Marea Therapeutics, secures $225 million private placement - Yahoo! Finance Canada
Lisata Therapeutics acquires Marea, raises $225 million - Investing.com
Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement - GlobeNewswire
Lisata Therapeutics Acquires Marea Therapeutics in $225 Million Financing to Advance Cardioendocrine Pipeline - Quiver Quantitative
Lisata Therapeutics Acquires Marea Therapeutics in $225 Million Financing to Advance Cardioendocrine Pipeline - Quiver Quantitative
Lisata Therapeutics acquires Marea Therapeutics, secures $225 million private placement - Yahoo Finance
3 Promising Penny Stocks With At Least $10M Market Cap - Sahm
3 Promising Penny Stocks With At Least $10M Market Cap - simplywall.st
Single investor holds 5% slice of Lisata Therapeutics (LSTA) - Stock Titan
Enterprise value to EBITDA forward of Lisata Therapeutics, Inc. – NASDAQ:LSTA - TradingView
Lisata Therapeutics Inc. (NASDAQ: LSTA) Share Price, LSTA Stock News, LSTA Share Price & Updates - kalkine.ca
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Lisata (LSTA) Trading Levels Update: Climbs 6.48% to $1.15 in the Latest Session; Technical Focus: $1.09 and $1.21 Define the Nearby Reference LevelsHull Moving Average - vinanet.vn
Enterprise value to EBITDA forward of Lisata Therapeutics, Inc. – FWB:8NE - TradingView
Lisata Therapeutics (LSTA) Drops 4.24% to $1.13, Approaching Critical SupportBlue Chip Entry Points - Vinanet
Enterprise value to EBITDA forward of Lisata Therapeutics, Inc. – SWB:8NE - TradingView
Lisata Therapeutics (LSTA) Slides 2.48% as Biotech Stock Holds Key SupportScalping Stock Signals - dars.gov.et
Enterprise value to EBIT forward of Lisata Therapeutics, Inc. – NASDAQ:LSTA - TradingView
Lisata Therapeutics (8NE) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Lisata Therapeutics Inc. (NASDAQ: LSTA) Share Price, LSTA Stock News, LSTA Share Price & Updates - Kalkine
Lisata Therapeutics (LSTA) Slips 0.93% as Shares Hover Near Key Support at $1.02Money Flow - vinanet.vn
LISATA THERAPEUTICS, INC. 2026: Revenue $0 EPS ($0.32) — 10-Q Summary - TradingView
Lisata Therapeutics Announces Major Workforce Reduction and Retrenchment - The Globe and Mail
Lisata Therapeutics Announces Major Workforce Reduction and Retrenchment - TipRanks
Lisata Therapeutics sues Kuva Labs, cuts 72% of workforce By Investing.com - Investing.com India
Lisata Therapeutics sues Kuva Labs, cuts 72% of workforce - Investing.com
Lisata Therapeutics, Inc. Continues to Evaluate Strategic Alternatives to Enhance Stockholder Value - marketscreener.com
Lisata Therapeutics (LSTA) Pursues Legal Action After Merger Ter - GuruFocus
Lisata Therapeutics, Inc. (LSTA) Files 8-K Announcing Retention Bonus Agreement With James Nisco - Minichart
Lisata Therapeutics Files Suit Against Kuva Labs, Reviews Strategic Alternatives and Cuts Workforce to Preserve Cash - Quiver Quantitative
Lisata Therapeutics sues Kuva Labs, cuts 72% of workforce By Investing.com - Investing.com UK
Lisata Therapeutics, Inc. Implements a Reduction in Force, Eliminating Approximately 72% of Full-Time Employees - marketscreener.com
Lisata Therapeutics terminates Dr. Kristen K. Buck as EVP R&D & CMO; James Nisco awarded $200,000 retention bonus - TradingView
Lisata Therapeutics moves forward with legal action following Kuva merger termination - Proactive financial news
CNSY Stock Price and Chart — NASDAQ:CNSY - tradingview.com
Lisata Therapeutics (LSTA) Drops 3.9% to $0.99 as Biotech Stock Presses Key SupportOrder Block - dars.gov.et
LSTA Q3 2025 Earnings: Narrower-than-Expected Loss Offers Modest Encouragement Despite Share DipEPS Surprise History - vinanet.vn
Lisata Therapeutics, Inc. Revenue Breakdown – NASDAQ:LSTA - TradingView
Kuva Labs (LSTA) ends Lisata cash-and-CVR tender offer after financing shortfall - Stock Titan
Lisata Therapeutics Inc (LSTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lisata Therapeutics Inc (LSTA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
1.49%
자본화:
|
볼륨(24시간):